Collegium Pharmaceutical, Inc. (COLL) — Fair Value Analysis
Base-case fair value (P50): $28.43 · Current price: $28.23 · Verdict: Fairly Valued
The Verdict on COLL
Based on our comprehensive Monte Carlo simulations, COLLEGIUM PHARMACEUTICAL INC (COLL) is currently assessed as Fairly Valued. The analysis indicates a median fair value (P50) of $28.43, which stands very close to the company's current trading price of $28.23. This results in a minimal +0.7% potential against the current price, reinforcing the fair valuation verdict. For investors monitoring COLL, this suggests the market is largely reflecting the company's intrinsic value as determined by our forward-looking models.
How COLL stacks up against peers
COLL's operational and financial health versus its sector peers is currently unrated, meaning we do not have a comparative quality tier assigned at this time. Despite the absence of a direct quality rating against other companies, the Monte Carlo simulation provides a robust, standalone assessment of COLL's valuation. The fair value conclusion, with $28.23 closely mirroring the $28.43, is derived from thousands of simulated forward scenarios of the company's fundamentals, rather than direct peer multiple comparisons. This independent valuation suggests COLL's current market price is an accurate reflection of its standalone potential.
What this means for investors
The "Fairly Valued" verdict for COLL, with $28.23 aligned to the $28.43 and a +0.7% indicated, implies that the immediate investment opportunity based purely on a valuation gap is limited. While the lack of a quality tier means we cannot definitively comment on its health versus peers, the Monte Carlo analysis suggests that COLL's fundamentals are already priced in. For those seeking significant alpha purely from undervaluation, COLL might not present that immediate opportunity. To explore the full spectrum of possibilities, including specific bear and bull case scenarios, and to track COLL's fair value as new fundamentals are released, sign up for a free FairCurve account.
Frequently Asked Questions
Is COLL overvalued or undervalued right now?
Based on our Monte Carlo simulations, COLLEGIUM PHARMACEUTICAL INC (COLL) is currently assessed as fairly valued. The median fair value (P50) is $28.43, which is very close to its current trading price of $28.23.
What is the bear case and bull case for COLL?
The full Monte Carlo distribution, including specific price targets for the bear (P10) and bull (P90) cases, along with the probability of upside, is exclusively available to users with a free FairCurve account.
How does FairCurve calculate COLL's fair value?
FairCurve determines COLL's fair value through a sophisticated Monte Carlo simulation, running thousands of forward scenarios to account for various fundamental inputs and market conditions. This provides a robust probability-weighted valuation.
How can I track COLL's fair value as it changes?
You can add COLLEGIUM PHARMACEUTICAL INC (COLL) to your free FairCurve watchlist to receive daily fair-value updates and instant re-valuation alerts whenever new earnings reports or significant fundamental data are released.